Who Is a Good Candidate for Hormone Replacement Therapy?

The best candidates for hormone replacement therapy (HRT) are people with bothersome menopause or low-hormone symptoms.

They are generally healthy, with no personal history of hormone-sensitive cancer, blood clots, stroke, or active liver disease.

For menopausal women, this also means being within about 10 years of their last period, or under age 60 (The Menopause Society, 2022).

Outside those groups, HRT may still be an option. But the risk-benefit balance shifts, and it calls for a more careful, individualized conversation with a physician.

No one should start HRT based on symptoms alone. Candidacy is determined by history, exam, and lab work — not by a quiz or a marketing claim.

What This Means

If you’re dealing with hot flashes, night sweats, mood changes, low libido, fatigue, or other symptoms that seem hormone-related, HRT is worth discussing. But it isn’t automatically right for you.

Think of candidacy as a filter with two layers. First, do your symptoms and timing put you in a group where hormone therapy tends to help more than it hurts? Second, do you have any personal or family health history that changes that calculation?

A physician needs both pieces before recommending treatment. The answer is different for every patient.

Candidacy

Reasonable candidates for HRT generally include:

• Women experiencing moderate-to-severe hot flashes, night sweats, or vaginal/genitourinary symptoms of menopause, particularly within 10 years of menopause onset or before age 60, where the benefit-risk ratio is typically favorable (The Menopause Society, 2022).
• Men with laboratory-confirmed low testosterone accompanied by consistent symptoms — not low numbers alone, since testosterone therapy for men is governed by its own coverage and diagnostic criteria (Centers for Medicare & Medicaid Services, n.d.).
• Adults with earlier-than-average menopause or primary ovarian insufficiency, where hormone therapy is often recommended at least until the typical age of menopause to protect bone and cardiovascular health.
• People who are otherwise healthy, non-smokers, and without a personal history that falls into the higher-risk group below.

Poor or higher-risk candidates typically include:

• A personal history of breast, uterine, or other hormone-sensitive cancers.
• A history of blood clots (DVT or pulmonary embolism), stroke, or heart attack.
• Active or recent liver disease.
• Unexplained vaginal bleeding that hasn’t been evaluated.
• Starting more than 10 years past menopause onset, or being over 60 — this raises the risk of cardiovascular disease, stroke, blood clots, and dementia (The Menopause Society, 2022; Stuenkel et al., 2015).

Smoking and a strong family history of clotting disorders also shift someone into a higher-risk category. None of these automatically rule out every form of hormone support — but they change the conversation from “yes” to “let’s look closer.”

Clinical Evaluation

Determining candidacy isn’t a guess. A proper evaluation typically includes a detailed personal and family medical history (cancers, clots, cardiovascular disease, liver disease), a physical exam, and bloodwork — hormone levels along with relevant metabolic and safety labs.

For women, that may include a review of menstrual history and time since last period. For men, it means confirmed low testosterone on repeat morning labs plus symptom correlation.

Medicare’s own coverage criteria for testosterone treatment require documented low levels and consistent clinical findings, not symptoms alone (Centers for Medicare & Medicaid Services, n.d.).

Depending on findings, a physician may also order a mammogram, bone density scan, or cardiovascular risk assessment before starting therapy. The plan is revisited periodically rather than treated as a permanent decision (The Menopause Society, 2022).

Available Options

HRT is not the only option. A good evaluation should cover alternatives rather than assume hormones are the default.

For menopausal symptoms, non-hormonal prescription medications (certain antidepressants, gabapentin, and newer non-hormonal options), lifestyle changes, and vaginal (local) low-dose estrogen for genitourinary symptoms are all legitimate alternatives to systemic hormone therapy (Stuenkel et al., 2015).

For men with confirmed low testosterone, options range from lifestyle and weight management to testosterone replacement in its various forms (injections, gels, pellets), each with different cost, convenience, and monitoring tradeoffs.

Bioidentical compounded hormones are sometimes marketed as a “natural” alternative to FDA-approved products. But they are not FDA-approved, aren’t subject to the same manufacturing oversight, and shouldn’t be assumed to be safer (U.S. Food and Drug Administration, 2025).

Benefits, Limitations & Risks

Benefits

For the right candidate, HRT remains the most effective treatment for moderate-to-severe menopausal vasomotor symptoms and can help prevent bone loss (The Menopause Society, 2022).

For men with confirmed deficiency, testosterone therapy can improve energy, libido, and quality of life. But benefits aren’t guaranteed.

Results vary by individual, and therapy requires ongoing monitoring — it is not a one-time fix.

Limitations and risks

Limitations include the need for regular follow-up labs, and potential side effects — breast tenderness, bloating, mood changes, or, in men, changes in red blood cell counts or fertility. Hormone therapy treats symptoms rather than reversing aging.

Material risks — cardiovascular events, stroke, blood clots, and for some formulations, breast cancer risk — are real. They vary by age, timing, dose, and route of administration, and should be discussed individually rather than assumed away (The Menopause Society, 2022).

What the Evidence Shows

The evidence base is more nuanced than either “HRT is dangerous” or “HRT is risk-free” headlines suggest.

What's established

For women who start therapy close to menopause onset, symptom relief and bone protection benefits generally outweigh risks.

The FDA has recently moved to remove class-wide boxed warnings tied to cardiovascular disease, breast cancer, and dementia from estrogen-containing menopause products, citing outdated risk data drawn from an older trial population.

It kept some cardiovascular and breast cancer safety information in the label outside the boxed warning (U.S. Food and Drug Administration, 2025).

What evidence does not establish

Evidence does not establish that HRT is appropriate for everyone regardless of age or timing, that it prevents aging generally, or that compounded “bioidentical” formulations outperform FDA-approved products.

These claims are not supported by rigorous, controlled research (U.S. Food and Drug Administration, 2025; Stuenkel et al., 2015).

The endometrial cancer boxed warning for estrogen-containing products, notably, has not been removed. This underscores that the update is a targeted regulatory change, not a wholesale declaration that hormone therapy is risk-free.

Recovery / Next Steps

There’s no “recovery” from HRT in the surgical sense. But starting therapy is a process, not a single event. Most patients begin at a conservative dose, follow up within 6–12 weeks to reassess symptoms and side effects, and have labs rechecked periodically.

Many people notice initial changes within a few weeks, though full symptom response can take longer and may require dose adjustments. Therapy is reassessed on an ongoing basis — not something started once and left unexamined for years (The Menopause Society, 2022).

Orlando Considerations

Florida’s warm, humid climate can intensify certain menopausal symptoms like night sweats and skin changes. That’s one reason local demand for hormone evaluation runs high.

Patients should also know that not every hormone therapy provider in Florida is a physician. Advanced practice registered nurses can prescribe within their scope.

But non-primary-care services — including most hormone optimization and aesthetic-adjacent care — still require a formal collaborating physician relationship under Florida law (Fla. Stat. . 464.012, 2025).

Asking who is directly overseeing your evaluation and prescription, and confirming that person’s licensure, is a reasonable question at any Orlando-area practice, including ours.

Frequently Asked Questions

Can I get HRT if I’m over 60?

It’s not automatically ruled out. But the benefit-risk profile is less favorable when starting therapy more than 10 years past menopause onset or after age 60. That calls for a more cautious, individualized discussion with your physician (The Menopause Society, 2022).

Do I need bloodwork before starting HRT?

Yes. Candidacy is confirmed with a history, physical exam, and relevant labs — hormone levels plus safety labs — not symptoms alone. Men in particular need documented low testosterone on repeat testing (Centers for Medicare & Medicaid Services, n.d.).

Is bioidentical HRT safer than standard HRT?

Not by current evidence. Compounded “bioidentical” hormones are not FDA-approved and lack the same manufacturing and safety oversight as approved products (U.S. Food and Drug Administration, 2025).

What disqualifies someone from HRT?

A personal history of certain hormone-sensitive cancers, blood clots, stroke, active liver disease, or unexplained vaginal bleeding are the main red flags a physician screens for before recommending therapy.

How long does it take to know if HRT is working?

Many patients notice changes within several weeks, but a full assessment typically happens at the 6–12 week follow-up, with adjustments made from there.

References

Centers for Medicare & Medicaid Services. (n.d.). Local coverage determination: Treatment of males with low testosterone (L39086).

Fla. Stat. § 464.012 (2025). Licensure of advanced practice registered nurses; fees.

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236

The Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794.

U.S. Food and Drug Administration. (2025, November 10). HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy [Press release].

Last medically reviewed: August 20, 2026.

Related reading

• How Hormone Therapy Works: Pellets vs. Injection Hormones
• Low Testosterone Treatment Options Explained
• When Should You Start Hormone Replacement Therapy?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.